ArticleMedical oncology (Northwood, London, England)2011
VARS2 V552V variant as prognostic marker in patients with early breast cancer.
Article in Medical oncology (Northwood, London, England), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Impact of germline genetic variation on breast cancer prognosis: a systematic review and meta-analysis.BMC cancer · 2026Pooled it
- The Prognostic Value ofCancers · 2023Article
- VARS2 Depletion Leads to Activation of the Integrated Stress Response and Disruptions in Mitochondrial Fatty Acid Oxidation.International journal of molecular sciences · 2022Article
- The regulatory roles of aminoacyl-tRNA synthetase in cardiovascular disease.Molecular therapy. Nucleic acids · 2021Review
- A novel compound heterozygous mutation in VARS2 in a newborn with mitochondrial cardiomyopathy: a case report of a Chinese family.BMC medical genetics · 2018Article
- Accurate computation of survival statistics in genome-wide studies.PLoS computational biology · 2015Article
- A Comprehensive Prognostic Model for Colon Adenocarcinoma Depending on Nuclear-Mitochondrial-Related Genes.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study analyzed the polymorphisms of DNA repair genes and their impact on the survival of 240 patients with early breast cancer. The genomic DNA was extracted from paraffin-embedded tumor-free tissue or blood, and thirteen polymorphisms in 12 DNA repair genes were determined using the Sequenom Mass array system. Among the target polymorphisms, VARS2 rs2074511 and POLE rs5744857 were found to correlate with survival after curative surgery in a log-rank test. No difference was found in the clinical and tumor characteristics according to the genotypes of these two coding variants, except for a higher incidence of positive ER in patients with the GG genotype of POLE rs5744857 (P=0.025). Meanwhile, a multivariate analysis showed that the GG genotype of VARS2 V552 V (rs2301717) was significantly associated with disease-free survival (DFS; HR=0.298; P=0.044) and marginally with distant DFS (DDFS; HR=0.266; P=0.077). In particular, the VARS2 rs2074511 polymorphism was only associated with survival in patients with triple negative (TN)-type breast cancer (P=0.018 for DFS and 0.042 for DDFS, respectively). In conclusion, VARS2 V552V may be considered as a prognostic factor for survival in patients with early breast cancer.
Indexed as
Identifiers
20503108What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.